Demographic and clinical characteristics of patients not tested for the prothrombin gene mutation compared with those of investigated patients
| . | Patients not tested (N = 85) . | Patients tested (N = 251) . |
|---|---|---|
| Age (y) (median, range) | 65 (20-86) | 62 (23-84) |
| Sex (% male) | 58 | 52 |
| PDD (d) (median, range) | 7 (1-30) | 7 (1-30) |
| Risk factors for venous thrombosis (%) | ||
| recent surgery | 16 (19) | 53 (21) |
| recent trauma/fracture | 20 (24) | 51 (20) |
| estrogen therapy | 4 (5) | 18 (7) |
| pregnancy/childbirth | 1 (1) | 11 (4) |
| APC resistance/factor V mutation | 13 (15) | 41 (16) |
| Extent of deep-vein thrombosis (%) | ||
| isolated distal | 6 (7) | 15 (6) |
| proximal | 79 (93) | 236 (94) |
| Initial treatment (%) | ||
| unfractionated heparin | 59 (69) | 172 (69) |
| LMWH | 23 (27) | 65 (26) |
| other treatments | 3 (4) | 14 (6) |
| Recurrent VTE in 10-year follow-up (%) | 21 (25) | 68 (27) |
| . | Patients not tested (N = 85) . | Patients tested (N = 251) . |
|---|---|---|
| Age (y) (median, range) | 65 (20-86) | 62 (23-84) |
| Sex (% male) | 58 | 52 |
| PDD (d) (median, range) | 7 (1-30) | 7 (1-30) |
| Risk factors for venous thrombosis (%) | ||
| recent surgery | 16 (19) | 53 (21) |
| recent trauma/fracture | 20 (24) | 51 (20) |
| estrogen therapy | 4 (5) | 18 (7) |
| pregnancy/childbirth | 1 (1) | 11 (4) |
| APC resistance/factor V mutation | 13 (15) | 41 (16) |
| Extent of deep-vein thrombosis (%) | ||
| isolated distal | 6 (7) | 15 (6) |
| proximal | 79 (93) | 236 (94) |
| Initial treatment (%) | ||
| unfractionated heparin | 59 (69) | 172 (69) |
| LMWH | 23 (27) | 65 (26) |
| other treatments | 3 (4) | 14 (6) |
| Recurrent VTE in 10-year follow-up (%) | 21 (25) | 68 (27) |
PDD, patient-doctor delay, defined as the period elapsed between occurrence of first symptoms and referral to thrombosis center; APC,; LMWH, low-molecular–weight heparin; VTE, venous thromboembolism.